Addex Therapeutics Ltd - ADR earnings per share and revenue
On 04. Dez. 2025, ADXN reported earnings of -- USD per share (EPS) for Q3 25, -- the estimate of -- USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a --% difference. The market reacted with a -6.78% price change (close before vs. close after earnings).
Looking ahead to Q4 25, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Citius Pharmaceuticals Inc. Common
Report Date
26. Dez. 2025 For Q4 25
Estimate
-$0.49
Aktuell
-
Überraschung
-
FAQ
What were Addex Therapeutics Ltd - ADR's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Addex Therapeutics Ltd - ADR reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to Addex Therapeutics Ltd - ADR's Q3 2025 earnings?
The stock price moved down -6.78%, changed from $8.99 before the earnings release to $8.38 the day after.
When is Addex Therapeutics Ltd - ADR expected to report next?
The next earning report is scheduled for 06. Apr. 2026.
What are the forecasts for Addex Therapeutics Ltd - ADR's next earnings report?
Based on --
analysts, Addex Therapeutics Ltd - ADR is expected to report EPS of -- and revenue of -- for Q4 2025.